From Reuters.

Studies from Novo Nordisk will give the strongest indication yet of whether blockbuster GLP-1 drugs, a class being used by millions for diabetes and weight loss, can slow progress of Alzheimer’s disease.

#News #Reuters #Newsfeed #novonordisk #alzheimers

Read the story here: https://reut.rs/48oHZou

👉 Subscribe: http://smarturl.it/reuterssubscribe

Keep up with the latest news from around the world: https://www.reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en